ArticleNeuro-oncology practice2021
Impact of postoperative dexamethasone on survival, steroid dependency, and infections in newly diagnosed glioblastoma patients.
Article in Neuro-oncology practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 17 citations in OpenAlex.
- Prognostic associations of steroid use in patients with glioblastoma: A population-based study.Neuro-oncology practice · 2026Article
- The role of dexamethasone during treatment phases in glioblastoma: Insights from a retrospective observational study.Brain & spine · 2026Article
- Practice Variation in Perioperative Dexamethasone Use and Outcomes in Brain Metastasis Resection.JAMA network open · 2025Article
- Nanoparticle-in-Hydrogel Delivery System for the Sequential Release of Two Drugs.Pharmaceutics · 2025Article
- Dexamethasone in brain tumor patients: a real-world pharmacovigilance audit.Frontiers in neurology · 2025Article
- Proton pump inhibitors are detrimental to overall survival of patients with glioblastoma: Results from a nationwide real-world evidence database.Neuro-oncology practice · 2024Article
- Review
- Preoperative anemia is associated with prolonged hospital stay and increased facility discharges after glioblastoma resection.Frontiers in surgery · 2024Article
- Letter: are there incidences of clinically relevant psychiatric symptoms during glioblastoma treatment?Journal of neuro-oncology · 2023Article
- Characterization of perioperative glycemic status and dexamethasone use with associated postoperative complications in glioblastoma patients.Acta neurochirurgica · 2023Article
- Perioperative dexamethasone in high-grade gliomas: the short-term benefits and long-term harms.Frontiers in oncology · 2023Article
- Glucocorticoid Effects on Proteoglycans and Glycosaminoglycans.International journal of molecular sciences · 2022Review
- Prognostic factors for overall survival in elderly patients with glioblastoma: Analysis of the pooled NOA-08 and Nordic trials with the CCTG-EORTC (CE.6) trial.Neuro-oncology advancesArticle
- Impact of intensity-modulated proton therapy in reducing radiation-induced lymphopenia in glioma patients.Neuro-oncology advancesArticle
- Higher perioperative dexamethasone exposure is associated with shorter survival in glioblastoma.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe examined the effect of dexamethasone prescribed in the initial 3 postoperative weeks on survival, steroid dependency, and infection in glioblastoma patients.
methodsIn this single-center retrospective cohort analysis, we electronically retrieved inpatient administration and outpatient prescriptions of dexamethasone and laboratory values from the medical record of 360 glioblastoma patients. We correlated total dexamethasone prescribed from postoperative day (POD) 0 to 21 with survival, dexamethasone prescription from POD30 to POD90, and diagnosis of an infection by POD90. These analyses were adjusted for age, Karnofsky performance status score, tumor volume, extent of resection,
resultsPatients were prescribed a median of 159 mg [109-190] of dexamethasone cumulatively by POD21. Every 16-mg increment (4 mg every 6 hours/day) of total dexamethasone associated with a 4% increase in mortality (95% confidence interval [CI] 1%-7%,
conclusionsLower survival, steroid dependency, and higher infection rate in glioblastoma patients associated with higher dexamethasone administration in the initial 3 postoperative weeks. Nearly half of the glioblastoma patients are lymphopenic preoperatively and up to 1 month postoperatively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.